Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease
Authors:
Open Access
- 1 February 2011
- journal article
- Vol. 11 (2) , 103-106
Abstract
The aspartate aminotransferases (AST) to platelet ratio index (APRI) may serve as a noninvasive marker to assess liver fibrosis. To assess the diagnostic ability of the APRI for prediction of fibrosis in patients with chronic hepatitis B (CHB), chronic hepatitis C (CHC), and non-alcoholic fatty liver disease (NAFLD). This retrospective study included 207 patients with CHB, 108 with CHC, and 140 patients with NAFLD. The APRI was calculated as (AST level/upper normal limit for AST)/platelet counts (109/L) × 100. The stage of liver fibrosis in patients with chronic viral hepatitis was graded using the METAVIR scale. The Kleiner system for grading fibrosis was used in patients with NAFLD. Bivariate correlation analyses showed that the APRI was significantly associated with fibrosis scores in patients with CHC (p = 0.2634, p = 0.0059) and NAFLD (p = 0.2273, p = 0.0069), but not in those with CHB (p = 0.1005, p = 0.1495). Receiver operating characteristic (ROC) curves were used for assessing the ability of the APRI as a predictor of the absence or presence of liver fibrosis (fibrosis score of 0 vs fibrosis scores of 1-4). In patients with CHC, the APRI showed a sensitivity of 72.7% and a specificity of 62.4% for detection of fibrosis (p<0.01). In the NAFLD group, the APRI showed a sensitivity of 60.0% and specificity of 73.3% for detection of fibrosis (p<0.01). In patients with CHB, the APRI showed a sensitivity of 55.0% and a specificity of 75.4% for fibrosis (p=NS). The APRI shows an acceptable accuracy for the assessment of liver fibrosis in patients with CHC and NAFLD, but not in those with CHB.Keywords
This publication has 28 references indexed in Scilit:
- Estudio de concordancia en el grado de fibrosis hepáticaestimada mediante los índices bioquímicos APRI y FORNS, y la elastografía de transición (Fibroscan®) en pacientes coinfectados por VIH-VHCRevista Clínica Española, 2010
- A Comparative Study of Non-Invasive Methods for Fibrosis Assessment in Chronic HCV Infection2010
- Estudio retrospectivo de la capacidad de evaluación de fibrosis hepática del FibroScan®, APRI, FIB-4 y FORNS con referencia a la biopsia hepática de pacientes con hepatitis crónica C, mono y coinfectados con VIHGastroenterología y Hepatología, 2010
- Metabolic syndrome and non-alcoholic fatty liver diseaseAnnals of Hepatology, 2009
- Comparison of blood tests for liver fibrosis specific or not to NAFLDJournal of Hepatology, 2009
- Evaluation of diagnostic accuracy of APRI for prediction of fibrosis in hepatitis C patients.2008
- Simple Tests to Predict Hepatic Fibrosis in Nonalcoholic Chronic Liver DiseasesGut and Liver, 2007
- Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infectionLiver International, 2006
- Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver diseaseJournal of Gastroenterology and Hepatology, 2006
- Progression of liver fibrosis among injection drug users with chronic hepatitis C†Hepatology, 2006